ILJIN will have to have some truly compelling arguments to cause me to vote for their "team".
Current board and management have executed very well - meeting expectations and managing cash flow.
The only misstep that I see was choice of primary endpoint for VOS trial, and that was actually minor, in that the only problem was that both VOS and Restasis were well tolerated.
I see no reason to change horses in mid-stream.
I agree with management that this is unfortunate distraction at this time.